Furthermore, the evidence that exogenous hepcidin administration can ameliorate organ iron load without affecting anemia opens a new therapeutic field for hepcidin agonists/mimetics involving the treatment of different kinds of hemochromatosis (Figure 2). The gene discussed is HAMP; the disease is anemia.